
Earlier this week, Calibr-Skaggs announced two milestones in the clinical advancement of CLF065, its potential best-in-class, long-acting glucagon-like peptide-2 (GLP-2) receptor agonist in development for inflammatory bowel diseases (IBD). Calibr-Skaggs has enrolled the first patient in its Phase 2 study of CLF065 in chronic pouchitis and has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for a Phase 2, 105-patient study in Crohn’s disease. CLF065 is the first long-acting GLP-2 analog to enter Phase 2 trials specifically for IBD, with a pharmacology that supports the potential for once-monthly dosing intervals. “For people with IBD, today’s therapies focus almost entirely on suppressing inflammation, without repairing the damaged intestinal lining that drives the disease," says @AmyLightnerMD, chief medical officer at Calibr-Skaggs and principal investigator of the pouchitis study. "CLF065 is designed to both actively regenerate and repair the gut epithelium, thereby complementing anti-inflammatory agents to change the IBD treatment paradigm.” More: ow.ly/N9ux50Zbc6P























